| Ytd | 129.98% | |
| 1y | 561.00% |
| Open | 78.83 | Prev Close | 79.73 | Low | 77.50 | High | 80.50 | Mkt Cap | 7.05B |
| Vol | 1.31M | Avg Vol | 1.85M | EPS | 0.17 | P/E | 466.59 | Forward P/E | 14.31 |
| Beta | 0.59 | Short Ratio | 6.22 | Inst. Own | 70.24% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-12 | 50-d Avg | 57.98 | 200-d Avg | 38.85 | 1yr Est | 74.25 |
LQDA News
Top Wall Street analysts upgraded and downgraded several top companies, including Applied Materials,
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analys
Top Wall Street analysts changed outlook on top stocks. See all changes including upgrades, downgrad
B of A Securities analyst Jason Gerberry downgrades Liquidia (NASDAQ:LQDA) from Buy to Neutral an
Liquidia (NASDAQ:LQDA) released first-quarter financial results and hosted an earnings call on Monda
BTIG analyst Julian Harrison maintains Liquidia (NASDAQ:LQDA) with a Buy and raises the price tar
Liquidia Corporation (NASDAQ:LQDA), a biopharmaceutical company driven by science and compassion to
HC Wainwright & Co. analyst Andrew S. Fein maintains Liquidia (NASDAQ:LQDA) with a Buy and ra
Liquidia Corp (LQDA) reported better-than-expected Q1 results, with earnings of 52 cents per share a
Wall Street analysts changed outlook on top names. For full view of analyst rating changes, see anal
HC Wainwright & Co. analyst Andrew S. Fein maintains Liquidia (NASDAQ:LQDA) with a Buy and ra
Wells Fargo analyst Benjamin Burnett maintains Liquidia (NASDAQ:LQDA) with a Overweight and raise
Needham analyst Serge Belanger maintains Liquidia (NASDAQ:LQDA) with a Buy and raises the price t
BTIG analyst Julian Harrison maintains Liquidia (NASDAQ:LQDA) with a Buy and raises the price tar
US stocks rise, Nasdaq up 0.3%. Liquidia Corp (LQDA) beats Q1 expectations, shares rise 15.7%. Other
Liquidia (NASDAQ:LQDA) reported quarterly earnings of $0.52 per share which beat the analyst consens
Wells Fargo analyst Benjamin Burnett maintains Liquidia (NASDAQ:LQDA) with a Overweight and raise
Oppenheimer analyst Andreas Argyrides maintains Liquidia (NASDAQ:LQDA) with a Underperform and ra
Liquidia Corp (LQDA) reported mixed Q4 results, with earnings missing estimates but sales beating ex
Wells Fargo analyst Benjamin Burnett maintains Liquidia (NASDAQ:LQDA) with a Overweight and raise
HC Wainwright & Co. analyst Andrew S. Fein maintains Liquidia (NASDAQ:LQDA) with a Buy and ra
Liquidia (NASDAQ:LQDA) reported quarterly earnings of $0.15 per share which missed the analyst conse
Liquidia Corporation (NASDAQ:LQDA), a biopharmaceutical company revolutionizing care for patients wi
Jefferies analyst Amy Li maintains Liquidia (NASDAQ:LQDA) with a Buy and raises the price target
Liquidia Corporation (NASDAQ:LQDA), a biopharmaceutical company driven by science and compassion to
HC Wainwright & Co. analyst Andrew S. Fein maintains Liquidia (NASDAQ:LQDA) with a Buy and ra
Needham analyst Serge Belanger maintains Liquidia (NASDAQ:LQDA) with a Buy and raises the price t
Liquidia (NASDAQ:LQDA) reported quarterly losses of $(0.04) per share which beat the analyst consens
HC Wainwright & Co. analyst Andrew S. Fein reiterates Liquidia (NASDAQ:LQDA) with a Buy and m
Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company developing innovative therapies for